Panacea Biotec and ICMR Begin Phase III Trials for DengiALL®: A Step Forward in Dengue Prevention

Panacea Biotec, in partnership with the Indian Council of Medical Research (ICMR), initiated Phase III clinical trials for DengiALL®, a tetravalent dengue vaccine. Approved by the Drugs Controller General of India (DCGI), the trials will involve 10,335 participants across 19 sites in India. We appreciate the interest and support from the media and the public as we work towards this important health initiative.